Free Research Report on Jazz Pharmaceuticals, Inc., Furiex Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc., Prestige Brands Holdings, Inc. and Synta Pharmaceuticals, Inc.

NEW YORK, January 30, 2013 /PRNewswire/ --

Today, Traders Insight announced new research reports highlighting Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ), Furiex Pharmaceuticals, Inc. (Nasdaq: FURX), Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), Prestige Brands Holdings, Inc. (NYSE: PBH) and Synta Pharmaceuticals, Inc. (Nasdaq: SNTA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Jazz Pharmaceuticals, Inc. Research Report
The Full Research Report on Jazz Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-29/4e94_JAZZ]

Furiex Pharmaceuticals, Inc. Research Report
Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company's product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. Priligy (dapoxetine) is a drug developed for the on-demand treatment of premature ejaculation (PE). The Full Research Report on Furiex Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-29/64fa_FURX]

Sunesis Pharmaceuticals, Inc. Research Report
Sunesis Pharmaceuticals, Inc. (Sunesis) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The Company is focuses primarily on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is a anti-cancer quinolone derivative (AQD). The Full Research Report on Sunesis Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-29/669a_SNSS]

Prestige Brands Holdings, Inc. Research Report
Prestige Brands Holdings, Inc. (Prestige) is a holding company. The Company, along with its subsidiaries, is engaged in the marketing, sales and distribution of over-the-counter (OTC) Healthcare and Household Cleaning brands to mass merchandisers, drug stores, supermarkets, club and dollar stores primarily in the United States and Canada. The Company conducts its operations through two principal business segments: Over-the-Counter Healthcare and Household Cleaning. The Full Research Report on Prestige Brands Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-29/7623_PBH]

Synta Pharmaceuticals, Inc. Research Report
Synta Pharmaceuticals Corp. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases. As of December 31, 2011, it had two drug candidates in clinical trials for treating multiple types of cancer and several drug candidates in the preclinical-stage of development. The Full Research Report on Synta Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-29/8e0e_SNTA]


About Traders Insight
Our model of enabling open collaboration between members is breaking new ground into the investment community. By tapping into the resources of the community, we are crowd-sourcing our reach. As a result -- we have been able to identify some of the greatest moving companies on the market today. The evidence is in the results, join today and experience what you've been missing.


Press Contact:

Cora S. Patton
press@TradersInsight.net 
+1-203-297-6092 (North America)


SOURCE Traders Insight



Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.